Bazedoxifene: A selective estrogen-receptor modulator

Women's Health

Volumn 4, Issue 4, 2008, Pages 319-326

  Mitwally, Mohamed F M ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Bazedoxifene; Menopause; Osteopenia; Osteoporosis; Selective estrogen receptor modulators

Indexed keywords

ALENDRONIC ACID; APRELA; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; IBANDRONIC ACID; IBUPROFEN; MEDROXYPROGESTERONE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TAMOXIFEN; VITAMIN D;

ARTHRALGIA; ARTICLE; BIOEQUIVALENCE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; BREAST TENDERNESS; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOMETRIAL DISEASE; EPIDEMIC; EXERCISE; FRAGILITY FRACTURE; GLUCURONIDATION; HIGH RISK PATIENT; HORMONAL REGULATION; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; MASTALGIA; MENOPAUSE; MIGRAINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OSTEOPOROSIS; PERIPHERAL EDEMA; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; SIDE EFFECT; THERAPY EFFECT; THROMBOEMBOLISM; THROMBOPHLEBITIS; TREATMENT DURATION; UTERUS WEIGHT; VASOMOTOR DISORDER; VITAMIN SUPPLEMENTATION;

BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HOT FLASHES; HUMANS; INDOLES; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; WOMEN'S HEALTH;

EID: 48649103293     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.4.319     Document Type: Article

References (25)

1. Riggs BL, Hartmann LC: Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N. Engl. J. Med. 348(7), 618-629 (2003).
2. Stump AL, Kelley KW, Wensel TM: Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. Ann. Pharmacother. 41, 833-839 (2007).
3. NIH Consensus Development Panel on Osteoporosis Prevention D, and Therapy: Osteoporosis: prevention, diagnosis, and therapy. JAMA 285(6), 785-795 (2001).
4. US Department of Health and Human Services: Bone Health and Osteoporosis: a Report of the Surgeon General. Rockville, MD, USA. Public Health Service, Office of the Surgeon General (2004).
5. Riggs BL, Khosla S, Melton LJ 3rd: Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev 23(3), 279-302 (2002).
6. Barrett-Connor E, Wehren LE, Sins ES et al.: Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause 10(5), 412-419 (2003).
7. North American Menopause Society: Management of osteoporosis in postmënopausal women: 2006 position statement of The North American Menopause Society. Menopause 13 (3), 340-367 (2006).
8. Morello KC, Wurz CT, DeGregorio MW: Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. 42, 361-372 (2003).
9. Evista® (raloxifene hydrochloride), package insert. Eli Lilly and Company, IN, USA, July 2003.
10. Komm BS, Lyttle CR: Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY- 140424) for clinical evalution. Ann. NY Acad. Sci. 949, 317-326 (2001).
11. Miller CP, Collini MD, Tran BD et al.: Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J. Med. Chem. 44(11), 1654-1657 (2001).
12. Komm BS, Kharode YF, Bodine PV, Harris HA, Miller CP, Lyttle CR; Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146(9), 3999-4008 (2005).
13. Patat A, McKeand W, Baird-Bellaire S, Ermer J, LeCoz F: Absolute/ relative binavailability of bazedoxifene acetate in healthy postmenopausal women. Clin. Pharmacol. Ther. 73, (2003) (Abstract P43).
14. Ermer J, McKeand W, Sullivan P, Parker V, Orczyk G: Bazedoxifene acetate dose proportionality in healthy, postmenopausal women. Clin. Pharmacol. Ther. 73, (2003) (Abstract P46).
15. Chandrasekaran A, Ermer J, McKeand W et al.: Bazedoxifene acetate metabolic disposition in healthy, postmenopausal women. Clin. Pharmacol. Ther 73, (2003) (Abstract P47).
16. Gruber C, Gruber D: Bazedoxifene (Wyeth). Curr: Opin. Investig. Drugs 5, 1086 1093 (2004).
17. Komm BS, Lyttle CR: Developing a SFRM: stringent preclinical selection criteria leading to an acceptable candidate (WAY- 140424) for clinical evaluation. Ann. NY Acad. Sci. 949, 317-326 (2001).
18. Konini BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR: Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 46, 3999-4008 (2005).
19. Ronkin S, Northington R, Baracat E et al.: Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet. Gynecol. 105(6), 1397-1404 (2005).
20. Ronkin S, Baracat E, Roma L et al.: TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. Presented at: 83rd Annual Meeting of the Endocrine Society. Denver, CO, USA, 20-23 June 2001 489 (Abstract P3-145).
21. Boudes F, Ronkin S, Korner P, Baracat E, Constantine G: Effects of bazedoxifene TSE-424, a novel tissue selective estrogen receptor modulator SERM, on the incidence of breast pain. Osteoporos. Int. 14 (Suppl. 7), S14 (2003) (Abstract).
22. Ronkin S, Northington R, Baracat E et al.: Endometrial offects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet. Gynecol. 105, 1397-1404 (2005).
23. Ronkin S, Clarke L, Boudes P, Constantine G: TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. J. Bone Miner, Res. 16, S413 (2001) (Abstract).
24. Boudes P, Ronkin S, Korner P, Baracat E, Constantine G: Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain. Osteoporos. Int. 14, S14 (2003) (Abstract).
25. Miller PD, Chines A, Christiansen C et al.: Effects of bazedoxifene on bone mineral density and turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo- and active-controlled Study. J. Bone Miner. Ref. 23(4), 525-535 (2008).